Palisade Bio Inc. (PALI)
1.75
-0.08 (-4.37%)
At close: Jan 14, 2025, 3:59 PM
1.73
-0.86%
Pre-market Jan 15, 2025, 08:36 AM EST
undefined% (undefined)
| Bid | 1.73 |
| Market Cap | 4.83M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.26 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.76 |
| Volume | 248,324 |
| Avg. Volume (20D) | 1,355,926 |
| Open | 1.83 |
| Previous Close | 1.83 |
| Day's Range | 1.61 - 1.90 |
| 52-Week Range | 1.38 - 22.35 |
| Beta | undefined |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during int...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 30, 2007
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PALI
Website https://www.palisadebio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PALI stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 1218.05% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+68.57%
Palisade Bio shares are trading higher. The compan...
Unlock content with
Pro Subscription
2 months ago ·
Source
-12.26%
Palisade Bio shares are trading lower. The company announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood.
